Biotechs Face Higher Bar For Induced Infringement

Law360, New York (June 03, 2010, 2:17 PM ET) -- Patent claims covering methods of treatment; methods of performing certain diagnostic tests; and, increasingly, personalized medicine are common and important parts of patent portfolios developed by biotech and pharmaceutical companies. Patent owners, however, face a difficult hurdle in enforcing this type of claim against potential infringers.

These claims often are not infringed directly until individual physicians, laboratory technicians or even patients carry out the claimed method. For example, a method of treating a particular disease or condition by taking a drug or combination of drugs is...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles